Rigontec GmbH, which is developing RNA-based immunotherapeutics for cancer and viral diseases, has completed a €29.25 million series A funding with a final €15 million tranche issued to its venture capital shareholders.
Camstent Ltd, which is developing a bacteria-resistant polymer coating for medical devices, has raised £850,000 from a combination of existing and new investors to bring its first product to market – a polymer coated catheter designed to prevent urinary tract infections.
Bayer AG has raised its non-binding offer to buy Monsanto Co for a third time since May to $127.50 per share. A report in The Wall Street Journal on 5 September indicates that the two companies are having constructive talks.
In keeping with the widespread interest in precision medicine, OncoDNA SA, a privately held company that identifies cancer treatment options for doctors and patients, has raised €7.7 million in an equity placement.
Cell Medica Ltd has strengthened its hand in the field of T cell therapy with a new collaboration around T cell receptor technology. Having recently expanded a partnership with Baylor College of Medicine in Texas, US, and acquired the Delenex Therapeutics AG antibody company in Switzerland, the company has now entered into a partnership with University College London (UCL) to develop genetically engineered T cell receptor products for cancer.
AstraZeneca Plc is divesting a portfolio of small molecule antibiotics in line with its strategy of generating out-licensing revenue and tightening its therapeutic focus. In a deal announced on 24 August, the UK company said it will sell rights to the portfolio to Pfizer Inc which has a focus on infectious disease.
The London-based private equity firm Cinven Ltd is acquiring the US medical services company Bioclinica Inc for a reported $1.4 billion as an investment for its sixth capital management fund.
In preparation for splitting into two new listed business, Switzerland-based Galenica AG has decided to make a $1.53 billion US acquisition that will help one of the prospective companies, Vifor Pharma, get off to a strong start.
Amylyx Pharmaceuticals Inc has raised $5 million with a Series A equity placement that will top up its financing for a Phase 2 study of AMX0035, an experimental treatment for amyotrophic lateral sclerosis (ALS).
A Swedish start-up company that links patients with doctors via the internet has raised €6.1 million in seed funding from a syndicate led by Index Ventures and Stockholm-based Creandum AB. Berlin-based Project A Ventures GmbH also participated in the round.